Why the study?
Although direct oral anticoagulants may improve adherence compared with warfarin in atrial fibrillation, recurrent cardioembolic stroke still occurs due to non-adherence, particularly highlighting the need for simpler pharmacotherapy regimens.
Do direct oral anticoagulants (such as once-daily rivaroxaban) improve treatment adherence in patients with atrial fibrillation compared to warfarin?
Do direct oral anticoagulants (such as once-daily rivaroxaban) improve treatment adherence in patients with atrial fibrillation compared to warfarin?
Simpler pharmacotherapy regimens, such as once-daily direct oral anticoagulants like rivaroxaban, may improve medication adherence in elderly patients with atrial fibrillation.
May support once-daily rivaroxaban for adherence in AF; leaves open randomized comparisons versus warfarin.
Less onerous, compared with warfarin, treatment with direct oral anticoagulants (DOA) can lead to better adherence to treatment of patients with atrial fibrillation (AF). However, in a certain number of patients with AF, who were recommended by DOA, cardioembolic stroke recurs, which is largely due to the patients' failure to comply with medical recommendations. The appointment of DOA as first-line drugs does not guarantee a high adherence of patients with non-valvular AF. For elderly and old patients with AF and numerous comorbidities, the proposal of a simpler pharmacotherapy regimen is especially important. In a number of large modern studies performed in clinical practice, high adherence to rivaroxaban therapy has been established, which may be a result of taking this DOA 1 time per day, its safety and effectiveness.
No takes yet. Share an insight, caveat, or question.
С. Г. Канорский (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: